Background: Preoperative lymphoscintigraphy is without doubt a valid method for the detection of the sentinel lymph node (SLN). There has been considerable debate regarding the optimal site for the introduction of the tracer; various sites include peritumoral (PT), periareolar (PA), subdermal, and intradermal injection. Purpose: To evaluate retrospectively the lymphoscintigraphic identification rate of peritumoral (PT) injection versus subdermal periareolar (PA) injection in the detection of SLNs in breast cancer. Material and Methods: Between October 2002 and December 2011, a cohort of 906 consecutive patients with biopsy proven breast cancer underwent 914 SLN biopsy procedures. A total of 339 procedures (Group A) were performed using a PT deep injection of radiotracer while 575 procedures (Group B) adopted a subdermal PA injection of radiotracer towards the upper outer quadrant, regardless of the site of the carcinoma. All the patients underwent synchronous excision of the breast cancer and SLN biopsy. Results: SLNs were identified in the lymphoscintigram in 308/339 cases (90.85%) of Group A (PT injection) and in 537/ 575 cases (93.39%) of Group B (PA injection). Furthermore, in 2/339 patients (0.58%) of Group A, internal mammary lymph nodes were found at lymphoscintigraphy, whereas no internal mammary sentinel nodes were found in the Group B patients. The intraoperative identification rate of axillary SLNs was 99.41% (337 of 339) in the Group A patients and 99.65% (573 of 575) in the Group B patients. There was no significant difference in the two groups between the incidence of the number of SLNs detected and the incidence of identification of positive SLNs. Conclusion: PT versus PA injection of radiotracer showed comparable success rates for axillary SLN identification, and can be considered a rapid and reliable method.
with the highest probability of being involved in the case of lymphatic spread from the tumor.
Today SLNB represents a minimally invasive operative procedure that can accurately predict the status of axillary lymph nodes in clinical node-negative breast cancer patients and represents an alternative to conventional axillary lymph node dissection. The lymph drainage of the breast is relatively confined to the axilla but at times, though rarely, isolated lymphatic drainage of internal mammary chain-SLNs is reported (2.6-4%), and most surgeons therefore not always perform the routine removal of extra-axillary nodes. (10, 11) .
When the SLNB technique was introduced for the staging and treatment of breast cancer, preoperative lymphoscintigraphy was introduced accordingly (1-3, 12, 13) . There has been some debate about the optimal site for the introduction of the tracer. The various sites of injection include peritumoral (PT), periareolar (PA), subdermal, and intradermal injection (14, 15) . Despite such a wide variety of modalities utilized for tracer injection, the high rate of SLNs identification and the low incidence of false-negative cases are surprisingly homogeneous (16) . This observation has led to speculations that the site of injection is relatively unimportant, because the entire breast appears to drain to the same SLN (17, 18) .
The aim of our study was to evaluate retrospectively the lymphoscintigraphic identification rate of different radio colloid injection techniques, comparing PT injection versus subdermal PA injection in the detection of SLNs in breast cancer.
Material and Methods
A retrospective study was conducted on a cohort of 906 consecutive patients with biopsy proven breast cancer that underwent 914 SLNB procedures between October 2002 and December 2011. Eight patients had bilateral breast cancer. Patients with ductal carcinoma in situ diagnosed at needle core biopsy and patients with multifocal breast cancers were included in the study. Patients with cytological positive lymph nodes, with previous ipsilateral axillary surgery, and patients who received neoadjuvant chemotherapy before surgery were excluded from the study.
Lymphoscintigraphy
The lymphoscintigraphy injection protocol differed in the study period. From October 2002 to August 2006, 339 procedures (Group A) were performed using a PT deep injection of radiotracer in the breast parenchyma at four points. For non-palpable tumors the injection was performed using ultrasound or stereotactic guidance. From September 2006 to December 2011, 575 procedures (Group B) were performed using a subdermal PA injection of radiotracer towards the upper outer quadrant, regardless of the site of the carcinoma.
Lymphoscintigraphy was performed in the two groups of patients at least 15, 30, and 180 min after the administration of 40-60 MBq 99m Tc-labeled colloidal albumin in physiologic saline (Nanocoll Õ , GE Healthcare, Chicago, IL, USA). Images of the thoracic region at anterior and oblique projections, including the involved breast and axillary area, were acquired using a digital gamma camera computer system with a low-energy high-resolution collimator and an energy peak at 140 KeV (General Electric Millennium MG Gamma Camera Imaging System, Millennium GE, Milwaukee, WI, USA). Only the first hot spots outside the injection site were identified as SLNs. Subsequently a cobalt pen was used to locate the cutaneous projection of the SLN, and the skin overlying the hot spot was marked with a skin marker.
Surgical procedure
All the patients underwent synchronous excision of the breast cancer, either by conservative surgery or total mastectomy, and SLN biopsy. In cases of non-palpable breast lesions, a guidewire was placed in the tumor site under either stereotactic or ultrasonographic guidance.
For the intraoperative identification of the SLN a radio-guided surgical probe (Neoprobe neo2000 Gamma Detection Systems Õ -Neoprobe Corporation, Dublin, OH, USA) was used. In a very few cases, where the radio-guided surgical probe picked up a weak radiotracer signal, about 10 min before the beginning of surgery a subdermal PA injection of 0.5-0.8 mL of vital stain (Lymphazurin 1%) was performed. All hot and/ or blue lymph nodes were removed.
All SLNs were examined at frozen section. SLNs with a diameter <5 mm were frozen intact, whereas nodes with a diameter >5 mm were bisected longitudinally and frozen. Two 4 mm frozen sections were taken from the optimal cross-sectional surface of one half of the lymph node and stained with Hematoxylin and Eosin (H&E) for intraoperative examination. For definitive histopathological examination, all the remaining tissue was formalin-fixed and paraffinembedded.
All patients with SLN metastasis in frozen section (FS) underwent immediate completion of total axillary lymph nodes dissection (ALND). If the SLN was negative at FS but was found to contain metastasis in the final histopathology, patients underwent delayed completion of total ALND. No completion ALND was performed in women with metastasis-free SLNs.
Statistical methods
Chi-square test was performed to compare the rate between the different groups. P < 0.05 was considered to be statistically significant.
Results
The mean age of the patients was of 56.1 years (range, 35-81 years) in group A and of 54.7 years (range, 31-80 years) in group B. The features of the 914 tumors are indicated in Table 1 .
The average size of the tumors, evaluated on the widest lesion, was 19.7 AE 10.4 mm (range, 4-53 mm) in group A and of 21.2 AE 12.4 mm (range, 6-57 mm) in group B.
The lymphoscintigram demonstrated SLNs in 308 of the 339 cases (90.85%) of Group A (PT injection) ( Fig. 1 ) and in 537 of the 575 cases (93.39%) of Group B (PA injection) ( Fig. 2 ) (chi-square, 1.96;
Furthermore, in two of the 339 patients (0.58%) of Group A, internal mammary lymph nodes were found at lymphoscintigraphy, whereas no internal mammary sentinel nodes were found in the Group B patients. No differences in progression time of the radiotracer from the injection site were observed between the two groups of patients.
The intraoperative identification rate of axillary SLNs was 99.41% (337 of the 339 patients) in the Group A patients. In 29 of the patients, pre-operative lymphoscintigraphy did not identify the SLNs, which were, however, identified intraoperatively. In the Group B patients the intraoperative identification rate of axillary SLNs was 99.65 (573 of the 575 patients). In 36 of the 38 patients, preoperative lymphoscintigraphy did not identify the SLNs, which were, however, identified intraoperatively.
In four cases of failure to find the SLN, axillary lymphadenectomy was performed in any case on principle.
The average number of detected SLNs was 1.88 AE 0.9 in group A and 1.91 AE 0.7 in group B. The number of metastatic SLNs was 69 (20.3%) in group A and 114 (19.8%) in group B. The average number of detected SLNs and the incidence of positive SLNs were not significantly different between the groups of patients (chi-square 0.29; P ¼ 0.59).
Discussion
Various sites of injection including the PT, subdermal, intradermal, and PA have been described, but the optimal site of tracer injection has long been a matter of debate.
The first technique used in SLB was PT and this has become common in a clinical setting. Nevertheless, there are some difficulties involved by this method, particularly regarding the operator's experience in making the correct radiotracer injection, and also in the case of non-palpable tumors, where ultrasound or stereotactic guidance is required.
There are also other problems related to the fact that it is necessary to perform several injections in the peritumoral site, since the lymphatic structures, depending on their depth, may be represented in varying degrees, and may also be infiltrated by the tumor with reduced progression of the tracer, which will tend to accumulate at the injection site. For these reasons this approach has been criticized especially in non-palpable and multicentric tumors and in those lesions located in the upper outer quadrant because of the shine-through phenomenon determining high background noise in the axilla.
Subdermal PA injection of the radiotracer, more recently introduced, is a simple and easy method that does not require extensive experience (19) . Several studies have emphasized the importance of the subareolar lymphatic plexus on the basis of the high number of lymphatic tracts in this area compared with those in the breast parenchyma.
This finding may be explained by the embryologic development of the breast from the epithelium of the primitive milk streak. During development, lymphatic vessels elongate and grow synchronously in parallel with the growth of the lactiferous ducts, but they stay connected with the subareolar plexus. The subareolar plexus communicates with superficial and deep intramammary channels and drains into the regional lymph nodes via one or two large lymph trunks. These channels maintain their connection to the SA lymphatic plexus in the mature breast.
The hypothesis of the existence of a common plexus between deep and periareolar lymphatic vessels has been confirmed by several other authors (20, 21) .
In our retrospective study, we compared the lymphatic flow in the breast using the two injection sites PT and subdermal PA in two series of patients. In accordance with other authors, the results obtained confirm that the entire breast, including the nipple-areola complex, drains into the same axillary lymph nodes (22) (23) (24) . With subdermal PA injection a higher number of SLNs is identified (1.88 AE 0.9 vs. 1.91 AE 0.7) but it is most important to identify the node that is the first draining step of the tumor tissue, and lymphoscintigraphy is able to identify it with accuracy. In our experience, the rate of positive nodes is not significantly different in the two groups of patients.
Several authors state that PA injections detect fewer extra-axillary nodes than the PT injection (10, 11) . Borgstein et al. have also admitted that the only possible disadvantage of the PA injection lies in its inability to permit detection of accessory lymphatic pathways, especially with regard to the internal mammary chain (21) .
Our experience confirms this and, in fact, with the PA injection we did not find any nodes outside the axillary site, compared with the PT injection, where we found 4/796 internal mammary chain nodes (0.5%). Nevertheless, it must also be born in mind that most surgeons do not remove extra-axillary nodes routinely. However, the treatment of internal mammary chain nodes is a matter of debate; some authors affirm that dissection of the internal mammary chain lymph nodes benefits only a small portion of breast cancer patients, and would result in more injures to these patients and lead to more complications (25) (26) (27) . Several other authors are of a completely different opinion, stating that the therapy was altered in a substantial proportion of patients by internal mammary SLNB and survival was worse in patients who had internal mammary drainage that was not taken into account when adjuvant therapy was planned (28, 29) .
In our opinion, there are not enough published works on the subject, and more large clinical trials are necessary in order to explore the value of internal mammary node biopsy.
Finally, a slight improvement in the sensitivity of lymphoscintigraphy occurred in Group B patients compared with the Group A (90.85 vs. 93.39); in our opinion, this was due to the optimization of the technique by the medical staff concerned.
The results obtained confirm the hypothesis that the lymphatic pathways draining different areas of the breast parenchyma, and the subareolar plexus leads to the same sentinel lymph node. PT versus PA injection of radiotracer showed comparable success rates for axillary SLNs identification. PA injection of radiotracer showed comparable success rates for axillary SLNs identification.
In conclusion, we believe that the PA injection is to be considered the method of choice in the identification of SLNs. In fact, it can be considered a rapid and reliable method, with a low radiation dose for the patients that does not require either extensive experience on the part of the operator and or the use of ultrasound or stereotactic guidance in peritumoral injection for identifying SLNs in breast cancer patients. It is easy to perform, especially in non-palpable breast cancer.
